VIENNA—The bone microenvironment was regarded as a worthy target for breast cancer treatment in comments at the St Gallen Breast Cancer Conference from Michael Gnant MD, a Professor and Director of the Medical University of Vienna, who gave Oncology Times reporter Sarah Maxwell the latest data on the clinical potential of bone-directed therapies.
You may also like...
KRAS Mutation: Powerful Molecular Predictor of Cetuximab Response in Patients With Metastatic Colorectal Cancer 31 Aug, 2007 Colorectal cancer screening: survey of 11 European countries finds big mortality benefit 6 Nov, 2013 Which New Combination for Metastatic Renal Cell Cancer? 12 Nov, 2018 Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival 28 Jul, 2009
- Previous story BCL-2: A New Therapeutic Target in Estrogen-Receptor Positive Breast Cancer
- Next story Breast Cancer Prognostic Implications of Obesity and Insulin Resistance
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014